| InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 |
2024 results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the continued war in Gaza. InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to the southern facility. |
prnewswire.com |
2025-05-01 20:00:00 |
Czytaj oryginał (ang.) |
| InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak |
NEW YORK and HERZLIYA, Israel , Feb. 12, 2025 /PRNewswire/ -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr. |
prnewswire.com |
2025-02-12 20:35:00 |
Czytaj oryginał (ang.) |
| InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility |
The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war. The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders. |
prnewswire.com |
2024-12-20 10:32:00 |
Czytaj oryginał (ang.) |
| Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company |
InterCure Ltd. INCR has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates. |
benzinga.com |
2024-09-14 18:32:45 |
Czytaj oryginał (ang.) |
| InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million |
NEW YORK and HERZLIYA, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the six months ended June 30, 2024. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. |
globenewswire.com |
2024-08-29 22:03:00 |
Czytaj oryginał (ang.) |
| InterCure Announces Expansion of its Strategic partnership with Cookies to Germany |
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies' branded products, produced from its cultivation and manufacturing facilities, initially in 8 licensed branded pharmacies across. |
businesswire.com |
2024-08-28 12:54:00 |
Czytaj oryginał (ang.) |
| InterCure: A Cannabis Industry Leader Still Flying Under The Radar |
InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a positive 2023 ER. The company is entitled to full compensation from the Israeli government for the damage taken. |
seekingalpha.com |
2024-06-30 07:42:20 |
Czytaj oryginał (ang.) |
| InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference |
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City. This prestigious event will bring together senior management teams from leading cannabis companies including InterCu. |
businesswire.com |
2024-05-22 10:45:00 |
Czytaj oryginał (ang.) |
| InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million |
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. FY2023 Financial Highlights and Milestones Annual revenue for the year ending December 31, 2023 was NIS 356 million, and the adjusted EBITDA for the year ending December 31, 2023 was NIS 61 million, approximately 17% of revenues, a. |
businesswire.com |
2024-05-01 12:27:00 |
Czytaj oryginał (ang.) |
| InterCure: Bargain Israel Cannabis Play |
InterCure Ltd. has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel, but is expected to recover. The cannabis market in Israel is still limited to medical use, with expansion to medical cannabis patient access to grow the market in 2024. InterCure stock is cheap at only about 1x sales, with catalysts for growth in 2024 and beyond. |
seekingalpha.com |
2024-04-22 19:41:00 |
Czytaj oryginał (ang.) |
| InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint |
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the “CannG” Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months. While the Canna. |
businesswire.com |
2024-03-22 13:58:00 |
Czytaj oryginał (ang.) |
| PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape |
LONDON--(BUSINESS WIRE)---- $INCR #CannG--The PESG Research has released an industry update following the regulatory shifts in Germany. Germany is expected to pass the Cannabis Act today (Friday), heralding a transformative era for the medical cannabis industry. This legislative milestone, by removing cannabis from the 'narcotics act', is set to significantly ease the prescription process for medical cannabis, heralding profound implications for medical professionals, patients, and companies operating within th. |
businesswire.com |
2024-02-23 14:12:00 |
Czytaj oryginał (ang.) |
| InterCure Provides an Update Regarding Nir Oz Facility |
NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company's press release issued on October 17, 2023, in which the Company provided an update regarding the status of the security situation in Israel, and its impact on the Company and its employees, the Company is providing an additional update regarding the status of its facility in Kibbutz Nir Oz (the “Southern Israel Site”). |
globenewswire.com |
2024-02-13 18:46:00 |
Czytaj oryginał (ang.) |
| InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain |
NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “Agreement”) with the shareholders of Leon Pharm Ltd. (the “Sellers”, and “Leon Pharm ”, respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing medical cannabis in Israel, by way of a share purchase of all of the issued and outstanding share capital of Leon Pharm (the “Transaction”). |
globenewswire.com |
2024-01-31 11:27:00 |
Czytaj oryginał (ang.) |
| InterCure Wins Cannolam Arbitration Proceeding |
NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company's press release issued on August 31, 2023, in which the Company reported that the Tel Aviv-Jaffa District Court dismissed the lawsuit that filed against the Company by minority shareholders of its subsidiary, Cannolam Ltd. (“Cannolam”), and the parties agreed on a binding arbitration process (the “Arbitration”), in which the amount owed to the Company and the parties will be determined and paid as part of a full separation process, the Company hereby reports that the Arbitration has been concluded, and the arbitrator has decided in favor of the Company on most of the claims presented to him by the Company, while rejecting almost all of the claims presented by the minority shareholders. |
globenewswire.com |
2023-10-31 18:39:00 |
Czytaj oryginał (ang.) |
| InterCure Provides an Update Regarding the Security Situation in Israel |
NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, today addressed the status of the security situation in the State of Israel, and its impact on the Company and its employees. |
globenewswire.com |
2023-10-17 21:04:00 |
Czytaj oryginał (ang.) |
| InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY |
Achieved record revenues of NIS 209 million ($ 7 5 million) 1 for the first half of 2023 |
globenewswire.com |
2023-08-31 23:45:00 |
Czytaj oryginał (ang.) |
| InterCure: Leader In Israel's Growing Medical Cannabis Market |
In mid-August, InterCure, one of the leaders in the global medical cannabis market, will publish financial results for the 2nd quarter of 2023. According to the Ministry of Health, the consumption of medical cannabis in Israel rose to 4.88 tons in June 2023 from 3.47 tons in June 2021. At the end of April 2023, a partnership was signed with Mike Tyson to distribute, cultivate and manufacture all TYSON 2.0 products in Israel, Australia, and certain European countries. |
seekingalpha.com |
2023-08-02 23:22:35 |
Czytaj oryginał (ang.) |
| InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE |
NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Compan y"), announced today that its board of directors (“Board”) has approved the voluntarily delisting of the Company's common shares (“Shares”) from the Toronto Stock Exchange (the “TSX”) (the “Delisting”). |
globenewswire.com |
2023-07-10 21:00:00 |
Czytaj oryginał (ang.) |
| InterCure Ltd. (INCR) Q4 2022 Earnings Call Transcript |
InterCure Ltd. (NASDAQ:INCR ) Q4 2022 Earnings Conference Call April 4, 2023 4:30 PM ET Company Participants Alexander Rabinovitch - CEO & Director Amos Cohen - CFO Conference Call Participants Vivien Azer - Cowen and Company Matt Bottomley - Canaccord Genuity Pablo Zuanic - Zuanic & Associates Operator Thank you for standing by, and welcome to InterCure's Fourth Quarter 2022 Earnings Call. |
seekingalpha.com |
2023-04-04 22:56:07 |
Czytaj oryginał (ang.) |
| InterCure Reschedules 2022 Full Year Results Conference Call |
NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022. |
globenewswire.com |
2023-04-03 19:27:00 |
Czytaj oryginał (ang.) |
| InterCure: Why The Company Is Grossly Undervalued By Wall Street |
InterCure earned CAD$39 million in Q3 2022, up 61.2% from the previous year. Moreover, at the end of Q4 2022, the total number of licensed patients using cannabis for medical purposes in Israel was 123,212, up 13,860 from the previous year. |
seekingalpha.com |
2023-01-20 14:22:25 |
Czytaj oryginał (ang.) |